Atrogin-1 is known to result in cachexia-induced muscle atrophy, and TJ-41 treatment ameliorates muscle weight loss in mouse cancer models together with decreased IL-6 production in macrophages [24], further suggesting that TJ-41 treatment might repress atrogin-1 in the cachexia-induced muscle atrophy. This evidence concerns the gene IL6 and muscle atrophy.